Krka, d. d. (FRA:KN8)

Market Cap	7.30B +37.9%
Revenue (ttm)	2.04B +6.9%
Net Income	403.24M +13.0%
EPS	13.21 +13.9%
Shares Out	n/a
PE Ratio	18.11
Forward PE	18.04
Dividend	9.10 (3.79%)
Ex-Dividend Date	Jul 21, 2026

Volume	n/a
Average Volume	39
Open	237.00
Previous Close	243.00
Day's Range	237.00 - 237.00
52-Week Range	170.00 - 250.00
Beta	n/a
RSI	53.84
Earnings Date	May 14, 2026

About Krka, d. d.

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company’s prescription pharmaceuticals include medicines for the treatment of cardiovascular, gastrointestinal tract and metabolism, central nervous system, oncology, pain relief, antiinfectives for systemic use, antidiabetics, and other products. It provides non-prescription prod...

• Industry: Pharmaceutical Preparations
• Founded: 1954
• Employees: 13,236
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: KN8

Financial Performance

In 2025, Krka, d. d.'s revenue was 2.04 billion, an increase of 6.89% compared to the previous year's 1.91 billion. Earnings were 403.24 million, an increase of 12.96%.